Comparison

A10.7 cells

Item no. C0018006
Manufacturer Addexbio
Amount One Frozen vial
Category
Type Tumour Cells
Specific against Human (Homo sapiens)
Dry ice Yes
Citations 1.Bisht, S., Brossart, P., Maitra, A., and Feldmann, G. Agents targeting the Hedgehog pathway for pancreatic cancer treatment using A10.7 cells. Curr Opin Investig Drugs, 11: 1387-1398.
2.Feldmann, G., Fendrich, V., McGovern, K., Bedja, D., Bisht, S., Alvarez, H., Koorstra, J. B., Habbe, N., Karikari, C., Mullendore, M., Gabrielson, K. L., Sharma, R., Matsui, W., and Maitra, A. An orally bioavailable small-molecule inhibitor of Hedgehog signaling inhibits tumor initiation and metastasis in pancreatic cancer using A10.7 cells. Mol Cancer Ther, 7: 2725-2735, 2008.
3.Feldmann, G., Habbe, N., Dhara, S., Bisht, S., Alvarez, H., Fendrich, V., Beaty, R., Mullendore, M., Karikari, C., Bardeesy, N., Ouellette, M. M., Yu, W., and Maitra, A. Hedgehog inhibition prolongs survival in a genetically engineered mouse model of pancreatic cancer using A10.7 cells. Gut, 57: 1420-1430, 2008.
4.Feldmann, G., Dhara, S., Fendrich, V., Bedja, D., Beaty, R., Mullendore, M., Karikari, C., Alvarez, H., Iacobuzio-Donahue, C., Jimeno, A., Gabrielson, K. L., Matsui, W., and Maitra, A. Blockade of hedgehog signaling inhibits pancreatic cancer invasion and metastases using A10.7 cells: a new paradigm for combination therapy in solid cancers. Cancer Res, 67: 2187-2196, 2007.
5. Embuscado EE, Laheru D, Ricci F, Yun KJ, de Boom Witzel S, Seigel A, Flickinger K, Hidalgo M, Bova GS, Iacobuzio-Donahue CA. Immortalizing the complexity of cancer metastasis: genetic features of lethal metastatic pancreatic cancer obtained from rapid autopsy. Cancer Biol Ther. 4(5):548-54, 2005.
ECLASS 10.1 32160890
ECLASS 11.0 32160890
UNSPSC 41106509
Available
Description
Disease:
Pancreatic adenocarcinoma
Origin:
Derived from metastatic liver tumor (clinical stage IV)
Species:
Homo sapiens
Tissue:
Pancreas
Morphology:
Epithelial
Properties:
Adherent
Cytogenic data:
Tumorigenic in xenograft model, KRAS mutation: G12D, p53 mutation: WT, SMAD4 mutation: homozygous deletion.
Patient:
Male, Caucasian, 60 yrs of age
Medium:
AddexBio-formulated DMEM (C0003-01) + 10% FBS
Subculture:
1:2 to 1:4 using 0.25% trypsin or trypsin/EDTA, 5% CO2; 37C
Freezing Medium:
Complete culture medium supplemented with 5% (v/v) DMSO
Biosafety Level: I
Sterility:
Bacteria: Negative
Yeast: Negative
Mycoplasma: Negative
Pathogens:
HIV: Negative
Hepatitis B: Negative
Hepatitis C: Negative
Related cells by Organ: AR-42J cells
BxPc-3 cells
Capan-1 cells
MIA PaCa-2 cells
E3LZ10.7 cells
A10.7 cells
INS-1 cells
MIN-6 cells
Storage condition
LN2
Manufacturer - Category
Cell Lines

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Amount: One Frozen vial
Available: In stock
available

Compare

Add to wishlist

Get an offer

Request delivery time

Ask a technical question

Submit a bulk request

Questions about this Product?
 
Close